Haemonetics (HAE) Stock Forecast & Price Target

Compare

403 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HAE Analyst Ratings

Moderate Buy

8 Buy

2 Hold

1 Sell

Based on 11 analysts giving stock ratings to

Haemonetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HAE Stock 12 Month Forecast

Average Price Target

$78.70

▲(45.77% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Haemonetics in the last 3 months. The average price target is $78.70 with a high forecast of $105.00 and a low forecast of $61.00. The average price target represents a 45.77% change from the last price of $53.99.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"60":"$60","83":"$83","106":"$106","71.5":"$71.5","94.5":"$94.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$78.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$61.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[60,71.5,83,94.5,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.77,77.09538461538462,79.42076923076922,81.74615384615385,84.07153846153847,86.39692307692307,88.7223076923077,91.0476923076923,93.37307692307692,95.69846153846154,98.02384615384615,100.34923076923077,102.67461538461538,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.77,75.07230769230769,75.37461538461538,75.67692307692307,75.97923076923077,76.28153846153846,76.58384615384615,76.88615384615385,77.18846153846154,77.49076923076923,77.79307692307692,78.09538461538462,78.39769230769231,{"y":78.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.77,73.71076923076923,72.65153846153846,71.59230769230768,70.53307692307692,69.47384615384615,68.41461538461539,67.35538461538461,66.29615384615384,65.23692307692308,64.17769230769231,63.11846153846154,62.059230769230766,{"y":61,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":84.08,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.05,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.77,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$105.00

Average Price Target$78.70

Lowest Price Target$61.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rohin K Patel

J.P. Morgan

$62

Hold

14.84%

Upside

Downgraded

08/11/25

Haemonetics downgraded to Neutral from Overweight at JPMorganHaemonetics downgraded to Neutral from Overweight at JPMorgan

Andrew Cooper

Raymond James

$105→$78

Buy

44.47%

Upside

Downgraded

08/11/25

Haemonetics downgraded to Outperform from Strong Buy at Raymond JamesHaemonetics downgraded to Outperform from Strong Buy at Raymond James

Anthony Petrone

Mizuho Securities

$90→$70

Buy

29.65%

Upside

Reiterated

08/08/25

Haemonetics price target lowered to $70 from $90 at MizuhoHaemonetics price target lowered to $70 from $90 at Mizuho

David Rescott

Robert W. Baird

$87→$72

Buy

33.36%

Upside

Reiterated

08/08/25

Haemonetics price target lowered to $72 from $87 at BairdHaemonetics price target lowered to $72 from $87 at Baird

Craig Bijou

Bank of America Securities

―

Sell

―

Reiterated

08/08/25

Haemonetics (HAE) Receives a Sell from Bank of America Securities

Michael Petusky

Barrington

$95→$86

Buy

59.29%

Upside

Reiterated

08/08/25

Barrington lowers Haemonetics price target, says pullback 'too much'Barrington lowers Haemonetics price target, says pullback 'too much'

Jack Scalprey

TR | OpenAI - 4o

$85→$61

Hold

12.98%

Upside

Downgraded

08/08/25

Joanne Wuensch

Citi

$90→$78

Buy

44.47%

Upside

Reiterated

08/07/25

Citi Sticks to Its Buy Rating for Haemonetics (HAE)

Marie Thibault

BTIG

$85

Buy

57.44%

Upside

Reiterated

08/07/25

Haemonetics: Strong Plasma Performance and Growth in Blood Management Justify Buy Rating Despite Interventional Challenges

Michael Matson

Needham

$84→$68

Buy

25.95%

Upside

Reiterated

08/07/25

Haemonetics' Strong Financial Performance and Strategic Adjustments Justify Buy Rating Despite Challenges

David Turkaly

Citizens JMP

$100

Buy

85.22%

Upside

Reiterated

05/20/25

Citizens JMP reiterates Market Outperform Rating on Haemonetics (HAE)Citizens JMP analyst David Turkaly reiterated a Market Outperform rating and $100.00 price target on Haemonetics (NYSE: HAE).

Kristen Stewart

C.L. King

$116

Buy

114.85%

Upside

Initiated

09/13/24

Haemonetics initiated with a Buy at CL KingHaemonetics initiated with a Buy at CL King

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rohin K Patel

J.P. Morgan

$62

Hold

14.84%

Upside

Downgraded

08/11/25

Haemonetics downgraded to Neutral from Overweight at JPMorganHaemonetics downgraded to Neutral from Overweight at JPMorgan

Andrew Cooper

Raymond James

$105→$78

Buy

44.47%

Upside

Downgraded

08/11/25

Haemonetics downgraded to Outperform from Strong Buy at Raymond JamesHaemonetics downgraded to Outperform from Strong Buy at Raymond James

Anthony Petrone

Mizuho Securities

$90→$70

Buy

29.65%

Upside

Reiterated

08/08/25

Haemonetics price target lowered to $70 from $90 at MizuhoHaemonetics price target lowered to $70 from $90 at Mizuho

David Rescott

Robert W. Baird

$87→$72

Buy

33.36%

Upside

Reiterated

08/08/25

Haemonetics price target lowered to $72 from $87 at BairdHaemonetics price target lowered to $72 from $87 at Baird

Craig Bijou

Bank of America Securities

―

Sell

―

Reiterated

08/08/25

Haemonetics (HAE) Receives a Sell from Bank of America Securities

Michael Petusky

Barrington

$95→$86

Buy

59.29%

Upside

Reiterated

08/08/25

Barrington lowers Haemonetics price target, says pullback 'too much'Barrington lowers Haemonetics price target, says pullback 'too much'

Jack Scalprey

TR | OpenAI - 4o

$85→$61

Hold

12.98%

Upside

Downgraded

08/08/25

Joanne Wuensch

Citi

$90→$78

Buy

44.47%

Upside

Reiterated

08/07/25

Citi Sticks to Its Buy Rating for Haemonetics (HAE)

Marie Thibault

BTIG

$85

Buy

57.44%

Upside

Reiterated

08/07/25

Haemonetics: Strong Plasma Performance and Growth in Blood Management Justify Buy Rating Despite Interventional Challenges

Michael Matson

Needham

$84→$68

Buy

25.95%

Upside

Reiterated

08/07/25

Haemonetics' Strong Financial Performance and Strategic Adjustments Justify Buy Rating Despite Challenges

David Turkaly

Citizens JMP

$100

Buy

85.22%

Upside

Reiterated

05/20/25

Citizens JMP reiterates Market Outperform Rating on Haemonetics (HAE)Citizens JMP analyst David Turkaly reiterated a Market Outperform rating and $100.00 price target on Haemonetics (NYSE: HAE).

Kristen Stewart

C.L. King

$116

Buy

114.85%

Upside

Initiated

09/13/24

Haemonetics initiated with a Buy at CL KingHaemonetics initiated with a Buy at CL King

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Haemonetics

1 Month

xxx

Success Rate

14/30 ratings generated profit

Average Return

+0.19%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.67% of your transactions generating a profit, with an average return of +0.19% per trade.

3 Months

xxx

Success Rate

25/50 ratings generated profit

Average Return

+0.86%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +0.86% per trade.

1 Year

Anthony PetroneMizuho Securities

Success Rate

27/50 ratings generated profit

Average Return

+5.37%

reiterated a buy rating 4 days ago

Copying Anthony Petrone's trades and holding each position for 1 Year would result in 54.00% of your transactions generating a profit, with an average return of +5.37% per trade.

2 Years

xxx

Success Rate

22/50 ratings generated profit

Average Return

+21.84%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 44.00% of your transactions generating a profit, with an average return of +21.84% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HAE Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HAE has received 11 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. HAE average Analyst price target in the past 3 months is 78.70.

Each month's total comprises the sum of three months' worth of ratings.

HAE Financial Forecast

HAE Earnings Forecast

Next quarter’s earnings estimate for HAE is $1.13 with a range of $1.08 to $1.20. The previous quarter’s EPS was $1.10. HAE beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.65% of the time in the same period. In the last calendar year HAE has Outperformed its overall industry.

HAE Sales Forecast

Next quarter’s sales forecast for HAE is $313.99M with a range of $301.73M to $325.28M. The previous quarter’s sales results were $321.39M. HAE beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year HAE has Outperformed its overall industry.

HAE Stock Forecast FAQ

What is HAE’s average 12-month price target, according to analysts?

Based on analyst ratings, Haemonetics Corp.’s 12-month average price target is 78.70.

What is HAE’s upside potential, based on the analysts’ average price target?

Haemonetics Corp. has 45.77% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HAE a Buy, Sell or Hold?

Haemonetics Corp. has a consensus rating of Moderate Buy which is based on 8 buy ratings, 2 hold ratings and 1 sell ratings.

What is Haemonetics Corp.’s price target?

The average price target for Haemonetics Corp. is 78.70. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $105.00 ,the lowest forecast is $61.00. The average price target represents 45.77% Increase from the current price of $53.99.

What do analysts say about Haemonetics Corp.?

Haemonetics Corp.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of HAE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Haemonetics (HAE) Stock Forecast & Price Target

HAE Analyst Ratings

HAE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Haemonetics

HAE Analyst Recommendation Trends

HAE Financial Forecast

HAE Earnings Forecast

HAE Sales Forecast

HAE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts